You are here: Industry Insights > drug

News List

CN Bio licences Hepatitis B drug discovery programme from Bristol-Myers Squibb pharmaceutical-technology
April 10, 2017
UK’s CN Bio Innovations has licenced a Hepatitis B drug discovery programme from Bristol-Myers Squibb Company.
RedHill Biopharma’s Yeliva obtains orphan drug designation from US FDA pharmaceutical-technology
April 10, 2017
RedHill Biopharma’s Yeliva (ABC294640) has secured orphan drug designation from the US Food and Drug Administration...
Orphan status for GW’s rare epilepsy drug pharmatimes
March 31, 2017
London, UK-based GW Pharmaceuticals’ cannabinoid Epidiolex has been awarded Orphan status by European regulators as a treatment for Lennox-Gastaut Syndrome (LGS), a rare and severe form of childhood-onset epilepsy.
AZ’ neuromyelitis drug picks up Orphan status in EU pharmatimes
March 30, 2017
European regulators have awarded AstraZeneca’s inebilizumab (formerly MEDI-551) Orphan status for the treatment of neuromyelitis optica spectrum disorder (NMOSD), opening the ...
Perrigo completes sale of Tysabri drug royalty to RPI for $2.85bn pharmaceutical-technology
March 29, 2017
Drug manufacturer Perrigo has completed the sale of its right to the royalty stream from the global net sales of the drug Tysabri (natalizumab) to Royalty Pharma's (RPI) affiliate RPI Finance Trust for $2.85bn.
Smoking Slows Recovery From Drug Abuse drugs
March 28, 2017
People recovering from illicit drug abuse are more likely to be successful if they don't smoke cigarettes
Pfizer bags approval for RA drug Xeljanz pharmatimes
March 28, 2017
Some patients with moderate to severe forms of rheumatoid arthritis could get access to a new treatment option in Europe following the approval of Pfizer’s oral Janus kinase (JAK) ...
Shire’s rare blood disorder drug gets US fast track pharmatimes
March 24, 2017
An experimental therapy in development by Shire for patients with the rare blood disorder hereditary thrombotic thrombocytopenic purpura (hTTP) has been granted a fast track designation by the US Food and Drug Administration.
NICE backs use of drugs for breast cancer prevention pharmatimes
March 24, 2017
The National Institute for Health and Care Excellence has now published updated familial breast cancer guidelines which advocate the use of three medicines to reduce the risk of developing the disease.
British Columbia lists EPCLUSA on public drug plan to treat all six genotypes of chronic hepatitis C firstwordpharma
March 23, 2017
Gilead Sciences Canada, Inc. ( Gilead Canada ) today announced, effective March 21, 2017 , British Columbia will provide public access to EPCLUSA™ (sofosbuvir/velpatasvir) tablets.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 49 50 Next page